Business Wire

Denodo Launches New Data Integration Solution in the Cloud With Denodo Standard

31.3.2021 10:00:00 EEST | Business Wire | Press release

Share

Denodo, the leader in data virtualization, today announced Denodo Standard, a new data integration solution available on leading cloud marketplaces. The new offering leverages Denodo’s modern data virtualization engine to deliver superior performance and productivity, enabling real-time analytics and data services without replicating the data into another repository. Denodo Standard lowers the barriers to begin data integration by allowing organizations to purchase it directly from their cloud marketplace of choice—AWS, Microsoft Azure, and Google Cloud Platform. Its cloud infrastructure automation and flexible by the hour pricing enables both enterprises as well as small and medium businesses to rapidly deploy it without a large commitment of time and resources.

To begin a free trial of Denodo Standard on AWS, Azure, or Google Cloud click here.

Denodo Standard provides all the capabilities to quickly get data integration projects into production. Featuring an intuitive web user interface with a powerful no-code/low-code data design studio augmented by AI-powered suggestions and the option to choose from over 150 out-of-the-box connectors to various data sources, Denodo Standard delivers data quickly. The solution enables citizen integrators to connect to cloud data warehouses, data lakes, and SaaS applications, and combine the data from these disparate sources into a unified view for consumption by business users via dashboards and reports, or developers via APIs. Denodo’s modern data virtualization connects to data sources directly where the data resides, and provides an efficient way to make the integrated data securely available without the need to collect the data into an additional repository.

Key capabilities of Denodo Standard include:

  • High performance data virtualization engine to integrate and deliver data in real time.
  • Modern, unified Web UI with SSO (single sign on).
  • Integrated Apache-Zeppelin-based data science notebook.
  • Wizard-driven visual no-code/low-code design studio with auto-suggestions and autocomplete.
  • Zero-code creation of virtual models to expose data from any source to any consumer much faster.
  • No-code creation of data APIs: GraphQL, REST, OData with OAuth, SAML and Open API support.
  • Rich Cloud Connectivity including: Amazon Redshift, Azure Synapse Analytics, Databricks Delta, Google BigQuery, cloud data stores such as AWS S3, Azure Data Lake Storage, and Google Cloud Storage and SaaS apps like Salesforce, Marketo and Google Analytics.

For organizations that need additional data management features, such as the machine learning data catalog, they can seamlessly upgrade their solution to the Denodo Platform and expand their data integration layer into an advanced logical data fabric.

Forrester VP, Principal Analyst and author of The Forrester Wave™: Enterprise Data Fabric, Q2 2020, Noel Yuhanna wrote, “Denodo’s data fabric solution integrates key data management components including data integration, data ingestion, data transformation, data governance and security to support new and emerging use cases including Customers 360, real-time and on-demand analytics, IoT analytics, and self-service analytics. In addition, Denodo’s AI and ML capabilities, and automation also continue to enhance across data fabric components.”

To understand the differences between the Denodo Standard and the Denodo Platform capabilities, click here.

“The goal of Denodo Standard is to enable organizations of all sizes to unlock the value of their data assets faster, and with a lower cost and resource commitment. By leveraging cloud infrastructure automation, usage-based pricing, and free trials in the cloud marketplaces, we have lowered barriers to start using Denodo for data integration,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “We are excited to be able to bring the value of data virtualization to even more companies, especially small and medium-sized businesses, and we expect many of them to expand beyond their initial use quickly to the enterprise logical data fabric capabilities once they have realized the benefits and the rapid ROI Denodo provides.”

Please Tweet: News: @Denodo launches new fast and easy #dataintegration solution in the #cloud - “Denodo Standard”. Available on @awscloud @Azure @GoogleCloudTech. Free 30-day trial - https://www.denodo.com/en/denodo-platform/free-trials. Logical #datafabric #datavirtualization

About Denodo

Denodo is the leader in data virtualization providing agile, high-performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye